New anti-clotting drug more effective than current treatment

March 11, 2013, Brigham and Women's Hospital

A new and experimental anti-clotting drug, cangrelor, proved better than the commonly used clopidogrel and was significantly more effective at preventing blood clots in a large trial of patients who underwent coronary stent procedures. These data, from the phase III CHAMPION PHOENIX study, were presented at the American College of Cardiology's 62nd Annual Scientific Session and published simultaneously in the New England Journal of Medicine.

Researchers report that the new , which is administered intravenously, reduced the odds of complications from stenting procedures. Specifically, those who received cangrelor had a lower combined incidence of death, , ischemia-driven , or stent thrombosis at 48 hours after .

"We are very excited about the potential for this new medication to reduce complications in patients receiving coronary stents for a wide variety of indications. In addition to being much quicker to take effect and more potent than currently available treatment options, this is reversible and has a fast offset of action, which could be an advantage if is needed." said Deepak L. Bhatt, MD, MPH, lead author of the study, director of the Integrated Interventional Cardiovascular Program at Brigham and Women's Hospital (BWH) and chief of cardiology at VA Boston Healthcare System, as well as professor of medicine at Harvard Medical School.

In this randomized double-blind trial, researchers compared the novel IV drug cangrelor against the oral clopidogrel standard of care in approximately 11,000 patients at 153 centers around the world. The study included a wide selection of patients with different types of heart attack, angina, and other conditions for which people undergo percutaneous (PCI), as long as they did not have high risk for bleeding or recent exposure to other anti-clotting drugs.

Researchers report significantly better performance by cangrelor compared with clopidogrel:

  • A 22 percent reduction in the odds of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis at 48 hours after randomization: 4.7 percent vs. 5.9 percent
  • A 38 percent reduction in the odds of stent thrombosis at 48 hours: 0.8 percent vs. 1.4 percent
  • Both treatment arms showed a quite low, statistically comparable incidence in severe bleeding at 48 hours: 0.16 percent vs. 0.11 percent.
Coronary artery stents are used in the majority of patients who undergo percutaneous coronary intervention (PCI), a common medical procedure used to treat arteries in the heart that have become narrowed or blocked due to coronary artery disease, which affects an estimated 14 million Americans. During this procedure, patients are regularly given oral doses of an anti-clotting agent to prevent blood clotting. Both cangrelor and interfere with the P2Y12 receptor, a platelet-surface protein that helps regulate blood clotting.

"We are encouraged by these compelling results, especially as it relates to the safety data, and believe that this drug has the potential to offer dramatic benefits to our patients" said Robert A. Harrington, M.D., chairman of medicine at Stanford University School of Medicine and co-chair of the study.

The company plans to file for approval with the Food and Drug Administration using data from CHAMPION PHOENIX and the earlier BRIDGE trial.

Explore further: Novel anti-clotting drug more effective than Plavix in coronary procedures, study says

Related Stories

Novel anti-clotting drug more effective than Plavix in coronary procedures, study says

March 11, 2013
(Medical Xpress)—An experimental drug has been shown to be significantly more effective at preventing blood clots during coronary stenting procedures compared to the anti-clotting agent now typically used, according to ...

Complications in patients undergoing percutaneous coronary intervention tend to occur within first 30 days

March 24, 2012
Percutaneous coronary intervention (PCI), also known as coronary angioplasty or angioplasty, is a procedure used to treat acute coronary syndromes. PCI involves opening a blocked blood vessel by threading and inflating a ...

Results of the BRIDGE trial reported at TCT 2011

November 9, 2011
Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who required bypass surgery. Trial results were presented ...

Drug helps maintain platelet inhibition and anti-clotting levels prior to cardiac surgery

January 17, 2012
Patients who discontinued use of an antiplatelet agent such as clopidogrel prior to undergoing cardiac surgery to lower their bleeding risk and received intravenously the platelet inhibitor cangrelor achieved a higher rate ...

Recommended for you

A nanoparticle inhalant for treating heart disease

January 18, 2018
A team of researchers from Italy and Germany has developed a nanoparticle inhalant for treating people suffering from heart disease. In their paper published in the journal Science Translational Medicine, the group describes ...

Starting periods before age of 12 linked to heightened risk of heart disease and stroke

January 15, 2018
Starting periods early—before the age of 12—is linked to a heightened risk of heart disease and stroke in later life, suggests an analysis of data from the UK Biobank study, published online in the journal Heart.

'Decorated' stem cells could offer targeted heart repair

January 10, 2018
Although cardiac stem cell therapy is a promising treatment for heart attack patients, directing the cells to the site of an injury - and getting them to stay there - remains challenging. In a new pilot study using an animal ...

Two simple tests could help to pinpoint cause of stroke

January 10, 2018
Detecting the cause of the deadliest form of stroke could be improved by a simple blood test added alongside a routine brain scan, research suggests.

Exercise is good for the heart, high blood pressure is bad—researchers find out why

January 10, 2018
When the heart is put under stress during exercise, it is considered healthy. Yet stress due to high blood pressure is bad for the heart. Why? And is this always the case? Researchers of the German Centre for Cardiovascular ...

Heart-muscle patches made with human cells improve heart attack recovery

January 10, 2018
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.